Biocartis

🩸September is Blood Cancer Awareness Month🩸, a month in which we raise awareness on blood cancer - its types, signs, symptoms & impact - and give it the attention it needs! 🤔 Did you know that... 1️⃣ Acute Myeloid Leukemia (AML) is a rare type of blood cancer 2️⃣ IDH1 and IDH2 biomarkers are detected in 20% of AML cases 3️⃣ Our Idylla™ IDH1-2 Mutation Assay Kit (RUO*) can detect 5 mutations in the IDH1 gene and 10 mutations in the IDH2 gene 👉 https://lnkd.in/eDWUebSc *For Research Use Only (RUO), not for use in diagnostic procedures. #IDH1 #IDH2 #Biocartis #Idylla #BloodCancerAwarenessMonth #BloodCancer #AML

We're #hiring a new Senior Data Scientist in Mechelen, Flemish Region. Apply today or share this post with your network.

We're #hiring a new Salesforce Administrator / IT Support Specialist in Chicago, Illinois. Apply today or share this post with your network.

💡 Early detection and prompt treatment are crucial for lung cancer patients Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️ Learn more 👉🏻 https://lnkd.in/epGCuf_E #Biocartis #Idylla #EGFR #GeneFusion #ALK #ROS1 #RET #METex14 #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 #𝗘𝗖𝗣𝟮𝟬𝟮𝟱? 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁! 📍 Booth 52 | 🗓️ 6 - 10 September |🗺️ Vienna, Austria Stop by 𝗯𝗼𝗼𝘁𝗵 𝟱𝟮 to discover how Idylla™ can deliver your 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀! ⏱️ 👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 and get a live demo: https://lnkd.in/edUr5WCg 🎤 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝗿 𝗵𝗼𝘁𝘀𝗽𝗼𝘁 𝘀𝗲𝘀𝘀𝗶𝗼𝗻! On Tuesday 𝟵 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿, 𝟭𝟬:𝟬𝟬 𝗔𝗠 (CEST), Caroline JANS will be presenting the new 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗢𝗟𝗘-𝗣𝗢𝗟𝗗𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆 at the Hostpot Stage (Hall X5). This Assay is designed for the fast and straightforward detection of POLE and POLD1 mutations - key biomarkers associated with the hypermutated phenotype in endometrial cancer. 👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗔𝘀𝘀𝗮𝘆 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗶𝗺𝗲: https://lnkd.in/ewMDPyhG See you there? 👋 𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘗𝘖𝘓𝘌-𝘗𝘖𝘓𝘋1 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘈𝘴𝘴𝘢𝘺 𝘪𝘴 𝘧𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 (𝘙𝘜𝘖), 𝘯𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴. #Idylla #Biocartis #POLE #POLD1 #EndometrialCancer #MolecularDiagnostics #Pathology #ECP #ESP European Society of Pathology

🚀 𝗡𝗢𝗪 𝗔𝗩𝗔𝗜𝗟𝗔𝗕𝗟𝗘: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗢𝗟𝗘-𝗣𝗢𝗟𝗗𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆* ✅ Molecular classification of #EndometrialCancer samples in ~ 95 min. ✅ Covers 99% of the known pathogenic #POLE & #POLD1 mutations ✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024) ✅ Fit for use on small biopsies & directly from 1 FFPE tissue section ✅ No need for sample batching  ✅ Straightforward results reporting 👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 https://lnkd.in/ewMDPyhG *For Research Use Only (RUO), not for use in diagnostic procedures. Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting. #Idylla #Biocartis #EC #MolecularDiagnostics 

🚨 𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 #𝗘𝗖𝗣𝟮𝟬𝟮𝟱? 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝗿 𝗛𝗼𝘁𝘀𝗽𝗼𝘁 𝗦𝗲𝘀𝘀𝗶𝗼𝗻! Join us for an exciting session on the brand-new 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗢𝗟𝗘-𝗣𝗢𝗟𝗗𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆 – designed for the fast and straightforward detection of POLE and POLD1 mutations - key biomarkers associated with the hypermutated phenotype in endometrial cancer. 👩🏫 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗙𝗮𝘀𝘁 & 𝗘𝗮𝘀𝘆 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗖𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗘𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗮𝗺𝗽𝗹𝗲𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗢𝗟𝗘-𝗣𝗢𝗟𝗗𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆 🎤 Caroline JANS, Senior European Market Manager at Biocartis 📅 Tuesday 9 September, 10:00 AM (CEST) 📍 ECP 2025, Hotspot Stage (Hall X5) 𝗪𝗵𝗮𝘁’𝘀 𝗶𝗻 𝗶𝘁 𝗳𝗼𝗿 𝘆𝗼𝘂? ✅ Molecular classification of endometrial carcinoma based on the latest international guidelines ✅ A closer look at the Idylla™ POLE-POLD1 Mutation Assay and its fully automated workflow ✅ Key insights from a multi-center investigation of endometrial cancer samples 👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗔𝘀𝘀𝗮𝘆: https://lnkd.in/ewMDPyhG 👉 𝗩𝗶𝘀𝗶𝘁 𝘁𝗵𝗲 𝗕𝗶𝗼𝗰𝗮𝗿𝘁𝗶𝘀 𝘁𝗲𝗮𝗺 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 𝟱𝟮 𝘁𝗼 𝗴𝗲𝘁 𝗮 𝗹𝗶𝘃𝗲 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗱𝗲𝗺𝗼! Idylla™ POLE-POLD1 Mutation Assay is for Research Use Only (RUO), not for use in diagnostic procedures. #EndometrialCancer #Idylla #POLE #POLD1 #Biocartis #ESPCongress #ESP #ECP2025 #ECP European Society of Pathology

Revolutionize your CRC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions and alleviate patient anxiety*! Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy. Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay. 👉 Read more https://lnkd.in/ew295pPq Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #MSI #RAS #NRAS #KRAS #BRAF #immunotherapy #ColorectalCancer #CRC *Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.

📢 𝗣𝗥𝗘𝗦𝗦 𝗡𝗘𝗪𝗦 We're excited to announce that Mike Kreitzinger has joined Biocartis as 𝐒𝐞𝐧𝐢𝐨𝐫 𝐕𝐢𝐜𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐆𝐥𝐨𝐛𝐚𝐥 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 🙌 In this role, Mr. Kreitzinger will lead our efforts to build partnership opportunities, forge alliances to drive commercial growth and expand the global integration of our precision oncology solutions. 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐰𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠 𝐌𝐫. 𝐊𝐫𝐞𝐢𝐭𝐳𝐢𝐧𝐠𝐞𝐫! 👏   💬 Mike Kreitzinger commented: “I am honored to join the stellar team at Biocartis as we advance the mission of providing rapid oncology biomarker results. Cancer is a disease of the genome, and rapid assessment enables providers the answers they need…when they need them. I am joining Biocartis to help shape the future of cancer care and look forward to establishing partnerships to bring ultra-fast biomarker testing closer to patients and their physicians.”   Mr. Kreitzinger brings a unique blend of business strategy, clinical diagnostic sales, and commercial leadership expertise to Biocartis. We look forward to the momentum he’ll help generate as we continue transforming cancer diagnostics with #Idylla™ 💪 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐬 𝐫𝐞𝐥𝐞𝐚𝐬𝐞 𝐡𝐞𝐫𝐞 👉 https://lnkd.in/eYx87EeW

📣 Molecular biomarker results in only 3 hours! THINK IDYLLA™ But what does ‘molecular’ actually mean?... 🤔 💡 ‘Molecular diagnostics’ or ‘molecular pathology’ involves analyzing molecules (such as DNA, RNA and proteins) from a tissue or liquid sample for presence of biological markers that can pinpoint the potential (re-)emergence of a specific disease, such as cancer, and aid in planning and monitoring the patient’s treatment. 👉 Idylla™ makes molecular diagnostics convenient, fast and suitable for any lab: https://lnkd.in/gh9nKbMA #Biocartis #Idylla #MolecularDiagnostics #MolecularPathology